Prostate cancer is prevalent in American men. In fact, it ranks second after skin cancer as the most common cancer in American men. The American cancer society predictions for 2018 stress the prevalence of prostate cancer in American men. The society expects over 165 thousand new cases of prostate cancer and 29 thousand deaths as a result of the disease.
In 2017, 161,360 men were diagnosed with prostate cancer. Mitt Romney, the former Republican presidential nominee, was among those diagnosed with prostate cancer last year. Romney joined the long list of American politicians including John Kerry, Colin Powell, etc. who have had a brush with prostate cancer. Like Kerry and Powell, Romney opted for surgery as opposed to undergoing radiation sessions meant to treat prostate cancer. And just like Kerry and Powell, Romney is a survivor of prostate cancer.
Prostate cancer ceased to be a death sentence disease, especially when diagnosed in time, according to Dr. David Samadi—a popular American urologist. Early diagnosis and treatment are the surest ways of beating back prostate cancer. The method of treatment (whether radiation or surgery) is a critical determinant of whether a patient survives prostate cancer or otherwise.
After many years of research and practice in diagnosis and treatment of prostate cancer, Dr. David Samadi is convinced that surgery is superior to radiation, especially when prostate cancer is budding. And the Lenox Hill Hospital-based urologist has many reasons to believe so. Dr. David Samadi draws from a study published in the journal “European Urology,” which was concluded on the premise that surgery is more effective than radiation therapy at treating localized prostate cancer. In addition, Dr. Samadi emphasizes that radiation therapy is capable of altering the human body at the cellular level resulting in secondary cancers. Rectal and bladder cancers are common among prostate cancer patients that opted for radiotherapy over surgery. What ‘s more, prostate cancer patients who choose radiation therapy are more likely—twice as likely—to die sooner than their counterparts, whose prostates are removed surgically.
Dr. David Samadi
A board-certified urologist, Dr. David Samadi is one of the most sought-after urologists in the U.S. The fact that he was the highest paid doctor—earning $7.6 million—in New York in 2012 speaks to the trust that people have on him.
Dr. David Samadi has been practicing medicine for over a decade. He started out his career at Columbia Presbyterian Hospital. He later moved to Mt. Sinai School of Medicine before commencing his tenure at Lenox.
link to article recap: https://www.researchgate.net/publication/322216785_The_effects_of_naloxone_on_human_breast_cancer_progression_in_vitro_and_in_vivo_studies_on_MDAMB231_cells
The enigma of human cell carcinoma and potential cures are tirelessly researched. Since 2010, peer-reviewed bio-medical journal, Oncotarget covers such ongoing oncology analysis and diligently publishes categories on a multitude of topics, including breast and thyroid cancers. Since human tumors respond to targeted cancer therapies different than say, rodent models, successful treatment remains elusive, time-consuming and exponentially expensive resulting in continued disease mortality. Watch this video on Youtube.
One example of inadequate pharmaceutical results in human breast cell line MDAMB231. While carcinoma research for this area of cells identified opioid receptor antagonist-drug naloxone as successful at inhibiting estrogen positive cells, it was only those specific cells that responded. Since cancer is more than just one disease, and every human patient has a unique combination of malignant cell function, finding a drug combination to inhibit each specific tumor cell growth continues to be inadequately researched for human cancer cell combinations. Rather, we spend resources to advance traditional chemo and radio-therapies.
While time is so often the enemy, one neoteric strategy is offering hope for drug-resistant cancers. On the cusp of a cure for both breast and more recently, recurrent thyroid cancer patients, the already FDA approved treatment for metastatic breast cancer palbociclib has Oncotarget’s full attention. Recurrent carcinoma frustrates both patient and oncologists because the original treatment stops responding effectively, allowing cancer to return. Excitement over palbociclib is to the extent that it works as a stronger “combination” with the original drug therapy vemurafenib, to induce ultimate cancerous cell death versus single drug treatment.
Protein complex cancers, especially common in thyroid cases, are more aggressive. Highly aggressive types of thyroid and breast cancer require ultimate vigilance and ongoing surveillance throughout the stages of treatment. Despite cancers that progress to an incurable state, there are still combinations yet to be found that will ultimately prolong life and enhance the quality of life for those being treated with poor prognosis. Learn more about Oncotarget at Eurekalert.org.
Battling cancer is the most related news in the century and breast cancer, alone, is one of the most common leading causes of death. Jim Dallke, Associate Editor of Chicago Inno stated that Tempus is the cancer-fighting startup that wants to give the physicians at the University of Chicago genomic sequencing data that will change how data will influence treatment success in the future. Data is important to use in medicine due to statistics, patterns and molecular spreadsheets.
Tempus`s founder Eric Lefkofsky started partnering with University of Chicago Medicine in 2015 and this year the project is taking off. This alliance is bound to provide data used to change treatment plans. The data sequencing will be used to monitor how patients respond to treatment plans. Genetic information isn`t sequenced enough so that physicians can improve treatment decisions, so the molecular data being processed will increase positive patient outcomes. Tempus steadily impacts the healthcare society and strives to accelerate private institutions order of science so that patients can go home to their families. Lefkosfy`s numerous community ventures started in Chicago, his hometown in which are initial startups called Groupon, Lightbank, and Drivin.
Who is Eric Lefkofsky?
Eric Lefkofsky graduated from the University of Michigan and is the CEO of Tempus and co-founder of several companies such as Groupon, Echo Global Logistics, InnerWorkings, Mediaocean and Uptake. He supports several ongoing charities by creating, buying and selling companies then giving a portion of that money back to the communities such as health, education, human rights, arts and culture. Lefkofsky`s confidence in business partnerships strengthens our outlook on the future of fighting cancer once and for all.
As he continues to change lives, accelerated disruption is proving to be one of his best idea for positive business outcomes for doctors, colleges, patient services and overall research science.